BUZZ-鼻腔药物在后期研究中达到试验目标，Lyra Therapeutics 公司业绩大涨

路透中文

Jun 02, 2025

BUZZ-鼻腔药物在后期研究中达到试验目标，<a href="https://laohu8.com/S/LYRA">Lyra Therapeutics</a> 公司业绩大涨

6月2日 - ** 药物开发商 Lyra Therapeutics LYRA.O 的股价盘前飙升 555% 至 31.80 美元

** 在一项后期试验中，Lyra的实验性药物LYR-210减轻了一种名为慢性鼻窦炎（Chronic Rhinosinusitis$(CRS)$）的鼻部疾病症状，包括鼻塞、流鼻涕和面部疼痛，该药物适用于没有鼻腔增生的患者(息肉)

** 慢性鼻炎是鼻腔和鼻窦的慢性炎症。

** 该药物达到了试验的主要和次要目标

** LYR-210是一种生物可吸收鼻腔植入物，能为患者提供6个月的持续用量

** 该公司表示，计划争取美国食品及药物管理局批准该药物用于无鼻息肉患者，并继续开发用于鼻息肉患者的药物

** 截至上一交易日收盘，LYRA股价累计下跌52.2

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540795584"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540795584\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540795584?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-02 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540795584","market":"us","top_or_hot":-1,"title":"BUZZ-鼻腔药物在后期研究中达到试验目标，Lyra Therapeutics 公司业绩大涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-鼻腔药物在后期研究中达到试验目标，<a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> 公司业绩大涨</title></head><body><p><span>6月2日</span><span> - </span> ** 药物开发商 Lyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>LYRA.O</span> 的股价盘前飙升 555% 至 31.80 美元</p><p> ** 在一项后期试验中，Lyra的实验性药物LYR-210减轻了一种名为慢性鼻窦炎（Chronic Rhinosinusitis<a href=\"https://laohu8.com/S/CRS\">$(CRS)$</a>）的鼻部疾病症状，包括鼻塞、流鼻涕和面部疼痛，该药物适用于没有鼻腔增生的患者(息肉)</p><p> ** 慢性鼻炎是鼻腔和鼻窦的慢性炎症。</p><p> ** 该药物达到了试验的主要和次要目标 </p><p> ** LYR-210是一种生物可吸收鼻腔植入物，能为患者提供6个月的持续用量 </p><p> ** 该公司表示，计划争取美国食品及药物管理局批准该药物用于无鼻息肉患者，并继续开发用于鼻息肉患者的药物 </p><p> ** 截至上一交易日收盘，LYRA股价累计下跌52.2 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-鼻腔药物在后期研究中达到试验目标，Lyra Therapeutics 公司业绩大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-鼻腔药物在后期研究中达到试验目标，Lyra Therapeutics 公司业绩大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-06-02 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-鼻腔药物在后期研究中达到试验目标，<a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> 公司业绩大涨</title></head><body><p><span>6月2日</span><span> - </span> ** 药物开发商 Lyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>LYRA.O</span> 的股价盘前飙升 555% 至 31.80 美元</p><p> ** 在一项后期试验中，Lyra的实验性药物LYR-210减轻了一种名为慢性鼻窦炎（Chronic Rhinosinusitis<a href=\"https://laohu8.com/S/CRS\">$(CRS)$</a>）的鼻部疾病症状，包括鼻塞、流鼻涕和面部疼痛，该药物适用于没有鼻腔增生的患者(息肉)</p><p> ** 慢性鼻炎是鼻腔和鼻窦的慢性炎症。</p><p> ** 该药物达到了试验的主要和次要目标 </p><p> ** LYR-210是一种生物可吸收鼻腔植入物，能为患者提供6个月的持续用量 </p><p> ** 该公司表示，计划争取美国食品及药物管理局批准该药物用于无鼻息肉患者，并继续开发用于鼻息肉患者的药物 </p><p> ** 截至上一交易日收盘，LYRA股价累计下跌52.2 </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nL3T3S50X7:1","article_id":"2540795584","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540795584","pubTimestamp":1748870970,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-鼻腔药物在后期研究中达到试验目标，Lyra Therapeutics 公司业绩大涨6月2日 -  ** 药物开发商 Lyra Therapeutics LYRA.O 的股价盘前飙升 555% 至 31.80 美元 ** 在一项后期试验中，Lyra的实验性药物LYR-210减轻了一种名为慢性鼻窦炎的鼻部疾病症状，包括鼻塞、流鼻涕和面部疼痛，该药物适用于没有鼻腔增生的患者(息肉) ** 慢性鼻炎是鼻腔和鼻窦的慢性炎症。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","LYRA":"Lyra Therapeutics"},"translate_title":"BUZZ-nasal drugs reach trial goals in late-stage studies, and Lyra Therapeutics' performance surges","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYRA":0.9},"content_text":"BUZZ-鼻腔药物在后期研究中达到试验目标，Lyra Therapeutics 公司业绩大涨6月2日 -  ** 药物开发商 Lyra Therapeutics LYRA.O 的股价盘前飙升 555% 至 31.80 美元 ** 在一项后期试验中，Lyra的实验性药物LYR-210减轻了一种名为慢性鼻窦炎（Chronic Rhinosinusitis$(CRS)$）的鼻部疾病症状，包括鼻塞、流鼻涕和面部疼痛，该药物适用于没有鼻腔增生的患者(息肉) ** 慢性鼻炎是鼻腔和鼻窦的慢性炎症。 ** 该药物达到了试验的主要和次要目标  ** LYR-210是一种生物可吸收鼻腔植入物，能为患者提供6个月的持续用量  ** 该公司表示，计划争取美国食品及药物管理局批准该药物用于无鼻息肉患者，并继续开发用于鼻息肉患者的药物  ** 截至上一交易日收盘，LYRA股价累计下跌52.2 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}